Donanemab in Early Symptomatic Alzheimer Disease

Overview of attention for article published in JAMA: Journal of the American Medical Association, August 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#29 of 37,609)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 4 public wall posts from 3 users.

[도나네맙 3상 임상시험 결과] • 경도인지장애(MCI)와 경증 알츠하이머병 환자 1,736명을 대상으로 항아밀로이드 항체 도나네맙을 74주간 4주마다 정맥투여 함. • 도나네맙을 투여하는 환자들을 (그룹 1) 타우 축적이 적거…

Hace unos días se publicaron los resultados del segundo ac anti-amiloide (donanemab) que ha demostrado eficacia en la…

https://jamanetwork.com/journals/jama/fullarticle/2807533

[항아밀로이드 항체 도나네맙의 3상 임상시험 논문] Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial …

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.